Topics:

Antiangiogenic Therapy for Metastatic Breast Cancer

Antiangiogenic Therapy for Metastatic Breast Cancer

Click here to earn Continuing Medical Education Credit

 

Introduction

Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer-related mortality, after lung cancer.1 The overall incidence of breast cancer was increasing until recently, but mortality has declined since 1990, presumably due to earlier detection and better treatments.1 Despite great advances in the current therapeutic options for the treatment of breast cancer, many patients will experience relapse and each year more than 40,000 women will die from metastatic breast (MBC).2

 

There are many approaches to the treatment of MBC, including chemotherapy agents, hormonal therapies, biologics, and supportive care. Significant advances have occurred with the development of novel antiangiogenic treatments that target growth factor receptor signaling pathways. One such pathway involves the vascular endothelial growth factor (VEGF) signal transduction, which is critical in angiogenesis and also important in tumor proliferation. This E-Update will focus on the role of angiogenesis in breast cancer and the impact of antiangiogenic therapy in the treatment of advanced breast cancer.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.